ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Greenhouse gas emissions & sustainability report data
In its 2023 reporting, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. disclosed greenhouse gas emissions of 1.6K tCO2e/year. By scope: Scope 1: 5.1 tCO2e/year; Scope 2: 1.6K tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
1.6K tCO2e/year
2023
Water Usage
4.7K tonnes/year
2023
Waste
14.48 tonnes/year
2023
Energy Use
2.3K kWh in '000s/year
2023
📊 Emissions by Scope (2023)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 1 | Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions). | 5.1 tCO2e/year |
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 1.6K tCO2e/year |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
✅ Reported Environmental Achievements
- Implemented energy-saving measures resulting in maintaining previous energy consumption levels while implementing further energy saving and emission reduction.
- Wastewater discharge pollutant concentration met the requirements of Pollutant Emission Standards for Biopharmaceutical Industry (DB31/373–2010), and LAS met the tertiary standard of Shanghai’s Comprehensive Wastewater Emission Standards (DB31/199– 2018).
🌱 ESG Focus Areas
Innovative R&DQuality management and controlIntellectual property protectionOccupational health and safetySupply chain managementEmployee training and developmentCorporate governanceInformation system managementOperational complianceData privacy protectionEmissions managementCooperation and developmentEmployee benefitsEnergy utilizationAnti-corruptionEmployment compliance, equity, and diversityPublic welfareClimate change management